Introduction
Heart failure hospitalizations continue to be a major cause of morbidity and mortality among invididual patients whilst presenting a serious economic and public health burden in the larger framework. 1 Over the next two decades, the total direct medical costs of cardiovascular disease (CVD) are projected to triple to $818 billion. 2 Six year mortality rates for heart failure patients are 84% in men and 77% in females. 3, 4 Given these overwhelming odds, it is imperative that preventative strategies continue to be investigated.
Elevated parathyroid hormone (PTH) levels have been associated with greater degrees of severity in heart failure. [5] [6] [7] [8] Indeed PTH levels have been suggested as potential biomarkers of risk for increased heart failure hospitalization rates. 9 Perhaps underlying this relationship is that fact that a direct link between the renin-angiotensin-aldosterone system and PTH has been demonstrated in humans. The implications of this are significant, and may present Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease potential therapeutic avenues for the treatment of a number of PTH-related conditions. 10 PTH levels are often measured in patients with chronic kidney disease (CKD) in order to evaluate and reduce the risk of renal osteodystrophy. [11] [12] [13] [14] Such data may yield useful information towards predicting patients at risk for further heart failure admissions. Whether this association between aldosterone and PTH levels persists among patient with CKD remains unknown. Whether this relationship can be manipulated by means of an aldosterone antagonist in order to prevent heart failure hospitalizations is also unknown.
We theorized that use of aldosterone antagonists in patients with CKD results in reduced serum PTH levels and that both these factors are associated with reduced hospitalization in patients with heart failure.
Methods
This is a retrospective study of adult (≥18 years) ambulatory patients who were diagnosed with chronic kidney disease stage 2 or worse as defined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 15 Patients with prior history of heart failure, on hemodialysis, with contraindications for spironolactone use, diagnosed malignancy, and acute renal failure were excluded from the study.
Cases.
A case was defined as an individual with CKD on spironolactone for a minimum duration of 12 months. We reviewed spironolactone prescriptions of patients with CKD between 2000-2005 and identified patients who had filled prescriptions for at least 12 months after commencement of the medication. Individuals were selected randomly using a random number generator. There were two prerequisites for selection of cases:
A serum parathyroid hormone level was measured
at least once in the year preceding the first prescription of spironolactone and that at least one parathyroid hormone level was obtained after 12 months of spironolactone use. We also stipulated a minimal interval of 18 months between measurement of the two assays. 2. All individuals had received a minimum of five years of follow-up care after the diagnosis of CKD had been made.
The control group (comparison group) was matched for age (for each year), gender, race, use of a vitamin D analogue, number of antihypertensive medications, and CKD stage from the Henry Ford Hospital database with at least two values of PTH 18 months apart and a follow up period of at least five years while off spironolactone. The study protocol was approved by the institutional review board.
Patient demographics, medications and other laboratory variables within three months of measurement of the second PTH level were collected. These were obtained by detailed chart review.
The primary outcome was heart failure exacerbation diagnosed by the presence of at least one symptom (shortness of breath, lower extremity swelling, orthopnea, or paroxysmal nocturnal dyspnea) and at least one sign (wet crackles, Jugular venous pressure (JVP)>5 cm, dependent edema) of heart failure along with chest radiograph findings or Brain Natriuretic Peptide (BNP)>100 pg/ml, that required hospital admission. These findings were checked for concordance with the diagnosis and treatment employed by the treating physician as evidenced by chart documentation. The secondary outcome was all-cause mortality which we identified through chart review and the social security death index.
Sample size calculation
In order to detect a mean difference of 20 pg/ml in the serum PTH level with a standard deviation (SD) of 120, a type I error of 0.05, and power of 80%, we calculated that the total required sample size would need to be 570 cases and controls.
Statistical analysis
Baseline characteristics were compared between the cases and the controls. Continuous variables were expressed in mean±SD. In the case of variables that did not follow a normal distribution, geometric means with 95% confidence intervals (CIs) were reported. Categorical variables were reported as percentages. The Student's t-test was used to compare continuous variables and chi-square or Fischer's exact test were used to compare categorical variables.
The hazard for heart failure hospitalizations amongst the cases was assessed by Cox conditional regression model adjusted for demographic, laboratory and historical covariates (age, gender, race, vitamin D levels, serum alkaline phosphatase, hypertension, diabetes, estimated glomerular filtration rate, and urine protein creatinine ratio)
Once spironolactone use was confirmed, we established an association of change in serum PTH levels with heart failure admissions in another Cox regression model adjusted for the same covariates given above.
After establishing this association, we employed regression models to evaluate the association between spironolactone use and changes in PTH levels and then to evaluate the association between PTH levels and heart failure hospitalizations. The regression coefficients of both of these models were used to calculate Sobel's test statistic. If significant, this statistic would indicate that change in PTH levels is a mediator of association between spironolactone use and heart failure hospitalization. All p-values were two-sided and p<0.05 was considered significant. Analyses were performed by using PASW v 18.0 (SPSS Inc., Chicago, Illinois, USA).
Results
There was a total of 425 cases and 425 controls; patients were matched for age, gender, ethnicity, number of blood pressure medications, vitamin D analogues, and CKD stage. Significant differences between the cases and the controls were noted in the serum levels of alkaline phosphatase as well as levels of PTH (Table 1) .
Spironolactone and its effect on PTH
The mean PTH level for cases prior to enrollment was 141±126 pg/ml and was not found to be significantly different from that of the controls 140±125 pg/ml (p=0.59).
After one year of spironolactone use, the cases were noted to have significantly lower levels of PTH when compared to the controls (101±87 vs 139±126, p<0.0001). The decrease in PTH levels was consistent across all stages of CKD amongst the cases, but not in the controls (Figure 1 ).
Spironolactone lowers rates of heart failure hospitalization
There were a total of 130 hospitalizations for heart failure with 48 instances among the cases and 82 in the controls. The hazard for heart failure hospitalization was lower in the cases than in the controls (HR 0.37; 95% CI 0.19-0.74, p=0.005). A Kaplan-Meier survival plot demonstrates this as a function of cases versus controls (log rank p-value<0.0001) (Figure 2 ). There were 369 deaths over a median follow up duration of 4.6 years (interquartile range (IQR) 3.3-5.8 years). Spironolactone use was not associated with reduction in all-cause mortality (HR 0.87; 95% CI 0.66-1.13, p=0.29). The Kaplan Meier plot demonstrates the survival probability of cases versus controls (log rank p-value=0.29) (Figure 3 ).
PTH mediates the association of spironolactone and decreased heart failure hospitalizations
In order to evaluate the role of PTH in the causal pathway of spironolactone and heart failure, we first evaluated the association of spironolactone use in a model adjusted for age, gender, race, vitamin D levels, serum alkaline phosphatase, hypertension, diabetes, estimated glomerular filtration rate, and urine protein creatinine ratio. After that, we added change in PTH levels in the model which led to significant change in effect size of association of spironolactone use and reduced risk of heart failure hospitalization (HR=0.47; 95% CI 0.23-0.96, p=0.04). There was a significant interaction of change in PTH and spironolactone use (p=0.002). To test significance of mediation, Sobel's test was used and found to be significant (test statistic 1.97, p=0.04). In a separate model adjusted for demographic and clinical covariates (age, gender, race, vitamin D levels, serum alkaline phosphatase, hypertension, diabetes, estimated glomerular filtration rate, and urine protein creatinine ratio), every 50 pg/ml increment in the serum PTH level was associated with increased hazard for heart failure hospitalization, (HR 1.25; 95% CI 1.09 -1.44, p = 0.002).
Discussion
In this study, we assessed the association between use of aldosterone antagonists, serum PTH levels and heart failure hospitalizations. We found that spironolactone use was associated with risk of heart failure hospitalization. Similarly, we found increased PTH levels were associated with risk of heart failure hospitalization. The association of spironolactone use with heart failure hospitalization was influenced by changes in PTH levels. Improved PTH levels in the spironolactone group (cases) additionally reduced the risk of heart failure hospitalization over and above that which was explained by spironolactone use only.
Two studies had previously evaluated the effect of mineralocorticoid receptor antagonism in lowering PTH in humans and attempted to elucidate the effects of aldosterone antagonist on PTH. Brown et al. used data from four human interventional studies and detected significant changes in PTH. 10 However, it is not a common practice to use aldosterone antagonists in CKD patients especially due to the great risk of hyperkalemia and the fact that a level of serum potassium ≥5.5 meq/l is considered a relative contraindication. 16 It is worth noting however that spironolactone is well tolerated in patients with mild to moderate CKD but requires close monitoring in the first month of its initiation. 17, 18 In our study, we had a one year incidence of mild hyperkalemia (5.5-6 meq/l) in 5% of cases and severe hyperkalemia (>6 meq/l) in 3% of cases compared to 4% mild hyperkalemia and 2% severe hyperkalemia in CKD patients not on spironolactone. The results of this study should be interpreted cautiously as hyperkalemia can increase the risk of fatal arrhythmias, and further risk benefit analysis of these findings needs to be validated.
Previous studies had not only associated elevated PTH levels with greater severity in heart failure patients but to also be independently associated with cardiovascular mortality in these patients. 19 The elevation in PTH seems to be driven by aldosterone related calcium wasting in the kidneys. 20 This pathway assumes a primary role for modulating PTH levels in patients with CKD due to inappropriate activation of the renin-angiotensin-aldosterone axis as a result of autoregulatory mechanisms in place to preserve glomerular filtration rate. [21] [22] [23] Brown et al. had speculated that aldosterone can directly act on mineralocorticoid receptors (MRs) at the parathyroid tissue to influence PTH synthesis as well as indirectly through increased urinary calcium excretion. This may explain why curative therapy for primary aldosteronism usually results in decreased PTH levels. 10 In another study, primary aldosteronism was associated with reduced serum calcium levels and increased baseline urinary calcium excretion. The authors of the study concluded that primary aldosteronism with secondary hyperparathyroidism can be treated with MR antagonists. 24 Sodium is another mediator which has been shown to impose adverse effects on the renal tubules through aldosterone. 25 Calcium homeostasis can influence renal sodium filtration and reabsorption which in turn could lead to the observed association in our study. 25 Elevated levels of aldosterone are often associated with heart failure, especially heart failure with preserved ejection fraction. 26 This study elucidates the pathophysiological basis of this observation. The findings of this study are consistent with several other studies illustrating the association between PTH and heart failure 5, 19, 27, 28 while also being inconsistent with some others. 29, 30 Though prior studies have shown similar associations, this is the largest study to date that has evaluated this relationship in patients with CKD. 31, 32 Moreover, this study attempts to explain the clinical association between the use of aldosterone antagonists and observed changes in PTH levels. 20 These findings are consistent with basic scientific literature supporting the claim that aldosterone-mediated effects on tissues rely on MR sensitivity and signaling. 33 Another observation of our study was that decreased levels of PTH associated with concurrent use of an aldosterone antagonist did not improve mortality rates when compared to the controls. One may surmise that individuals placed on aldosterone antagonists were more likely to have had severe resistant hypertension requiring more aggressive therapy and therefore our inability to demonstrate a mortality benefit when compared to the matched controls. CKD is a strong risk factor for heart failure with preserved ejection fraction. 34, 35 Aldosterone antagonists have not been shown to improve outcomes in individuals with heart failure with preserved ejection fraction. 36, 37 This may also be true for individuals with CKD.
Strengths of this study include the completeness of our data and the relatively prolonged follow-up duration for the cases and the controls given their continued care at the same institution. There remains the possibility, however, that some of these individuals may have been admitted to outside hospitals, rendering us unable to collect their information. All of our patients were insured and in instances where they were admitted outside our primary institution, they were eventually transferred back or subsequently followed up at our hospital system, further assuring us of the completeness of our follow up. The study is limited by its retrospective design and the fact that the clinical diagnosis was based upon documentation of the treating physicians which may have led to information bias. The study findings help to further our understanding of the mechanistic properties of aldosterone inhibition in individuals with CKD. In the future, a controlled study design may allow us to better interpret these findings.
Conclusions
This study attempts to describe the use of aldosterone antagonism and its effects on PTH in patients with CKD. It also explores the pathophysiological aspects of this pathway and their potential utility in reducing and preventing heart failure hospitalization in a subgroup of patients who, though not widely studied in heart failure trials, nevertheless account for a significant proportion of heart failure related hospitalizations.
